Journal
CLINICAL INFECTIOUS DISEASES
Volume 56, Issue 4, Pages 552-554Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis960
Keywords
hepatitis C virus; telaprevir; boceprevir; toxicity; duration
Categories
Funding
- NIAID NIH HHS [AI55397, T32 AI055397] Funding Source: Medline
Ask authors/readers for more resources
Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
